Table 1.

Demographic and clinical characteristics by the primary androgen deprivation treatment ADT failure group and the remaining cohort

	Primary ADT failure		Remaining cohort		P‐value	Total
	n	%	n	%		n	%
All cases	94	100.0	821	100.0	–	915	100.0
Age, years
<65	10	10.6	123	15.0		133	14.5
65–74	41	43.6	393	47.9		434	47.4
≥75	43	45.7	305	37.1	0.217	348	38.0
Initial treatment
Polyestradiol phosphate	44	46.8	414	50.4		458	50.1
TAB	50	53.2	407	49.6	0,579	457	49.9
Cardiovascular comorbidity
None	80	86.0	731	90.0		811	89.6
Present	13	14.0	81	10.0	0.354	94	10.4
Missing	1	–	9	–		10	–
Cancer‐related pain
No pain	21	22.3	356	43.6		377	41.4
Pain	73	77.7	460	56.4	<0.001	533	58.6
Missing	–	–	5	–		5	–
ECOG performance status
0	16	17.0	389	47.7		405	44.5
1	50	53.2	305	37.4		355	39.0
2–3	28	29.8	122	15.0	<0.001	150	16.5
Missing	–	–	5	–		5	–
Analgesic consumption
Negligible	21	22.3	414	50.7		435	47.8
≥1	73	77.7	402	49.3	<0.001	475	52.2
Missing	–	–	5	–		5	–
Grade of malignancy
WHO 1	12	13.3	124	15.5		136	15.3
WHO 2	34	37.8	380	47.5		414	46.5
WHO 3	44	48.9	296	37.0	0.086	340	38.2
Missing	4	–	21	–		25	–
T‐category
T0–T2	12	13.0	177	21.9		189	21.0
T3–T4	80	87.0	633	78.1	0.067	713	79.0
Missing	2	–	11	–		13	–
PSA, μg/L
PSA <100	24	25.5	223	27.3		247	27.1
PSA 100–500	39	41.5	353	43.3		392	43.1
PSA >500	31	33.0	240	29.4	0.770	271	29.8
Missing	–	–	5	–		5	–
Soloway score
1	14	15.1	305	37.8		319	35.4
2–3	79	84.9	502	62.2	<0.001	581	64.6
Missing	1	–	14	–		15	–
Hemoglobin, g/L
Median, q1–q3	108.5	11.3–129.0	125.0	11.6–141.0	0.004	124.0	11.6–140.0
Missing	0	–	12	–		12	–
SHBG
Median, q1–q3	47.5	39.8–53.3	39.5	28.0–57.8	0.164	42.0	29.3–57.0
Missing	78	–	711	–		789	–
Estradiol
Median, q1–q3	64.0	0.1–82.0	65.0	0.2–98.0	0.366	64.5	0.1–96.0
Missing	79	–	712	–		791	–
Testosterone
Median, q1–q3	12.0	8.3–16.6	13.2	10.0–17.4	0.042	13.0	9.8–17.2
Missing	11	–	79	–		90	–